{"id":389362,"date":"2020-11-30T07:08:28","date_gmt":"2020-11-30T12:08:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389362"},"modified":"2020-11-30T07:08:28","modified_gmt":"2020-11-30T12:08:28","slug":"uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/","title":{"rendered":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>~ <\/em><br \/>\n        <em>Strong <\/em><br \/>\n        <em>P<\/em><br \/>\n        <em>resence at ASH <\/em><br \/>\n        <em>Featuring<\/em><br \/>\n        <em>Five <\/em><br \/>\n        <em>P<\/em><br \/>\n        <em>resentations<\/em><br \/>\n        <em>, Including <\/em><br \/>\n        <em>Late-Breaking<br \/><\/em><br \/>\n        <em>Oral Presentation on <\/em><br \/>\n        <em>HOPE-B Pivotal Trial<\/em><br \/>\n        <em> ~<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>~ uniQure to Host <\/em><br \/>\n        <em>Investor <\/em><br \/>\n        <em>Webcast <\/em><br \/>\n        <em>Tuesday<\/em><br \/>\n        <em>, December 8, 2020 at 5:00 p.m. ET ~<\/em>\n      <\/p>\n<p align=\"justify\">LEXINGTON, Mass. and AMSTERDAM, Nov.  30, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p13kaCPzKF0Rs2HFaelmptODvCOevsgfJXxCxd6d9NdVVNQQfs4gtCzfVwOJQPjwLHnC01t8kM_8xpwy_C6AiQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">uniQure N.V.<\/a> (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,\u00a0today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62<sup>nd<\/sup> American Society of Hematology (ASH) Annual Meeting.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Dr. Pipe, principal investigator of the HOPE-B pivotal trial, will participate in the ASH press briefing scheduled for Monday, December 7 from 10:30 a.m. \u2013 11 a.m. E.T.<\/li>\n<li style=\"text-align:justify\">Dr. Pipe will present a late-breaking oral presentation on the HOPE-B data on Tuesday, December 8 at 11:45 a.m. E.T.<\/li>\n<\/ul>\n<p align=\"justify\">uniQure management along with Dr. Pipe will host an investor webcast on Tuesday, December 8, 2020, at 5:00 p.m. ET. To access the live webcast with presentation slides, please visit the Investor Relations section of uniQure\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ec0jJnwdXTOtkc3gDLB068qglpHlIDKEUEglnu7t1yLhAYKfbKDHbKwnDH38Rzl3L5QNY8Sfz8CtT5y0x4spJQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.uniQure.com<\/a>. The webcast will be archived for 90 days. The event also may be accessed by dialing (877) 870 \u2013 9135 for domestic callers and +44 020 719 283 38 for international callers. The passcode is 3164585. Please specify to the operator that you would like to join the \u201cuniQure Conference Call.\u201d<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">\n            <strong><br \/>\n              <u>Late-Break<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>ing<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u> Oral Presentation<\/u><br \/>\n            <\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">\u00a0<\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td>First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presenter:<\/strong>\n          <\/td>\n<td>Steven Pipe, M.D.<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Name:<\/strong>\n          <\/td>\n<td>Late-Breaking Abstracts, LBA-6<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Tuesday, December 8, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presentation <\/strong><br \/>\n            <strong>Time:<\/strong>\n          <\/td>\n<td>11:45 a.m. ET (8:45 a.m. PT)<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong><br \/>\n              <u>Oral Presentation<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td>\n            <em>Etranacogene Dezaparvovec (AAV5-Padua <\/em><br \/>\n            <em>hFIX<\/em><br \/>\n            <em> variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presenter:<\/strong>\n          <\/td>\n<td>Annette von Drygalski, M.D., PharmD<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Name:<\/strong>\n          <\/td>\n<td>801. Gene Editing, Therapy and Transfer I<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Monday, December 7, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presentation <\/strong><br \/>\n            <strong>Time:<\/strong>\n          <\/td>\n<td>2:45 p.m. ET (11:45 a.m. PT)<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong><br \/>\n              <u>Poster Presentations<\/u><br \/>\n            <\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Title:<\/strong>\n          <\/td>\n<td>\n            <em>AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Name:<\/strong>\n          <\/td>\n<td>801. Gene Editing, Therapy and Transfer: Poster III<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Monday, December 7, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presentation Time:<\/strong>\n          <\/td>\n<td>10:00 a.m. &#8211; 6:30 p.m. ET (7:00 a.m. &#8211; 3:30 p.m. PT)<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Title:<\/strong>\n          <\/td>\n<td>\n            <em>A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable <\/em><br \/>\n            <em>hFIX<\/em><br \/>\n            <em> Expression up to 18 Months after Dosing<\/em>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Name:<\/strong>\n          <\/td>\n<td>801. Gene Editing, Therapy and Transfer: Poster II<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Sunday, December 6, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presentation Time:<\/strong>\n          <\/td>\n<td>10:00 a.m. &#8211; 6:30 p.m. ET (7:00 a.m. &#8211; 3:30 p.m. PT)<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Title:<\/strong>\n          <\/td>\n<td>\n            <em>Examining the Hemophilia Disability Paradox<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session Name:<\/strong>\n          <\/td>\n<td>904. Outcomes Research\u2014Non-Malignant Conditions: Poster II<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Sunday, December 6, 2020<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Presentation Time:<\/strong>\n          <\/td>\n<td>10:00 a.m. &#8211; 6:30 p.m. ET (7:00 a.m. &#8211; 3:30 p.m. PT)<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The conference abstracts are available and can be accessed through this link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=84HlOweXTVHpwO-aj-kXkNVaNmnk-xz318GUE5jUslWbmS1slcVMtetqMD0_SguUZGsbbgDvTfzR7uppHaEJOK0V0M5s9nxwdGs_jqYfTIrX_i2986AJookx8zTv85h7\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ASH abstracts<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About uniQure <\/strong>\n      <\/p>\n<p align=\"justify\">uniQure is delivering on the promise of gene therapy \u2013 single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=crhwiHFIyL8uE9EE7HBz4PK67QAsNEH5-C0dXjuS307nAOJHQKE7GnC7SkQiq38p8pY-ZS97ZV-kVeQqIAWYuSqcybyVdJkjGgN-49V8npM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">pipeline<\/a> of proprietary gene therapies to treat patients with hemophilia B, Huntington&#8217;s disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ec0jJnwdXTOtkc3gDLB060ONWBBz_HP2UKkidYKGAzPyHtwzoFMOGJ3_W5vxAbbnT9hqYnZN3g_ADhPOJiyg-Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.uniQure.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>uniQure Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;look forward to&#8221;, &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions. Forward-looking statements are based on management&#8217;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to,\u00a0whether we will present long-term follow-up data from our hemophilia B gene therapy <\/em><br \/>\n        <em>studies, including two years of follow-up on the Phase IIb clinical trial of etranacogene dezaparvovec (AMT-061) and up to five years of follow-up from the Phase I\/II clinical trial of AMT-060, and whether we will announce top-line data from the pivotal HOPE-B study of etranacogene dezaparvovec before the end of this year. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators\u2019 clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in <\/em><br \/>\n        <em>uniQure\u2019s<\/em><br \/>\n        <em> Quarterly Report on Form 10-Q filed on\u00a0October 27, 2020. Given these risks, <\/em><br \/>\n        <em>uncertainties<\/em><br \/>\n        <em> and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>u<\/strong><br \/>\n        <strong>niQure Contacts:<\/strong><br \/>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:34%;width:34%;min-width:34%\">\n            <strong>FOR INVESTORS:<\/strong>\n          <\/td>\n<td style=\"max-width:32%;width:32%;min-width:32%\">\u00a0<\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%\">\n            <strong>FOR MEDIA:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Maria E. Cantor<\/strong>\n          <\/td>\n<td>\n            <strong>Chiara Russo<\/strong>\n          <\/td>\n<td>\n            <strong>Tom Malone<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Direct: 339-970-7536<\/td>\n<td>Direct: 617-306-9137<\/td>\n<td>Direct: 339-970-7558<\/td>\n<\/tr>\n<tr>\n<td>Mobile: 617-680-9452<\/td>\n<td>Mobile: 617-306-9137<\/td>\n<td>Mobile:339-223-8541<\/td>\n<\/tr>\n<tr>\n<td>\n            <a href=\"mailto:m.cantor@uniQure.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">m.cantor@uniQure.com<\/a>\n          <\/td>\n<td>\n            <a href=\"mailto:c.russo@uniQure.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">c.russo@uniQure.com<\/a>\n          <\/td>\n<td>\n            <a href=\"mailto:t.malone@uniQure.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">t.malone@uniQure.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d7cae656-03b3-4630-a397-cab817b94d3a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday , December 8, 2020 at 5:00 p.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,\u00a0today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. Dr. Pipe, principal investigator &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389362","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday , December 8, 2020 at 5:00 p.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,\u00a0today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. Dr. Pipe, principal investigator &hellip; Continue reading &quot;uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T12:08:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting\",\"datePublished\":\"2020-11-30T12:08:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/\"},\"wordCount\":882,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/\",\"name\":\"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\",\"datePublished\":\"2020-11-30T12:08:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk","og_description":"~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday , December 8, 2020 at 5:00 p.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) &#8212; uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,\u00a0today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. Dr. Pipe, principal investigator &hellip; Continue reading \"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T12:08:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting","datePublished":"2020-11-30T12:08:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/"},"wordCount":882,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/","name":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=","datePublished":"2020-11-30T12:08:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MzU2NyMzODQ3NjkwIzIwODA0MDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/uniqure-announces-multiple-presentations-and-investor-webcast-on-hemophilia-b-gene-therapy-program-at-the-62nd-american-society-of-hematology-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389362"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389362\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}